Skip to content
The Nexus
HEALTHJun 29 · 16:53 UTCMEDPAGE TODAY

FDA Expands Risankizumab Label in Psoriatic Disease

The FDA expanded the indications for risankizumab (Skyrizi) in plaque psoriasis and psoriatic arthritis to include treatment of children 6 years and older. AbbVie announced this update, noting risankizumab is an interleukin (IL)-23 antagonist.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
FDAorganizationAbbVieorganizationrisankizumabtopicSkyrizitopicplaque psoriasistopicpsoriatic arthritistopicchildren 6 years and oldertopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting